Mark Mondello
Analyst · Fox Advisors. Please proceed with your questions
Yes. First off, we hope to see you down here in Tampa, I think you're I think your team's playing in the Outback Bowl. So let us know if you're, if you're going to pop down in terms of in terms of gear, in terms of your question. The COVID situation, our team's done a first rate job. We, as we as we were going through the back half of 2021, we had, we had cases, largely driven on the Delta variant all over the world. And we were able to serve our customers do so really, really well. Not without some pain points. But again, I don't like to, I don't want to I don't want to start with our financial results. I want to start with the fact that we did a great job serving customers and an outcome for that was through it all, fiscal 2021. And for that sake, fiscal 2020. I think we navigated everything quite well, especially considering our geographic region and the scale of the company. As we sit today, more with Omicron I, let's keep our fingers crossed that maybe it appears to be a bit more contagious. Maybe not as severe time will tell. But we continue to do a really, really nice job in terms of managing that as well. As we think about some of the disruptions we had in Southeast Asia disruptions are still there but not to the magnitude that we've seen in the past. So fingers crossed. As we think about China, Mexico, U.S., and Eastern Europe, as we sit today, disruptions on a relative basis. So let's just say, let's just say for the last 18 months of hard, hard COVID, we see some periodic issues, but disruptions, I think, today are less than they've been in the last 14, 18 months. We continue to promote vaccinations around the world. We continue to promote booster shots. We continue to try to provide those on site. We sat in a status meeting last week, where as we get to the end of this calendar year 70%, 75% of our employees will be vaccinated. So I think that's helpful. I think we drive a lot of awareness. And then we also have very discipline protocols inside of our factories, mass or otherwise. I think all that is, is helping and, again, let's, let's keep good thoughts about, about this next derivation of, of the virus and, and hopefully, as we get into Calendar 2022, it will be manageable, like it has been the last couple years. In terms of our healthcare business, I would, I don't know that I'd call it boring. I think, I think I take that term as a positive where I take boring as consistent and reliable. And, boy, if that's the context to which you're for that. It, I think it's spot on. Here's a business where in fiscal 2019, we thought we would do about $3 billion in the healthcare space, we overshot that by $100 million $200 million. And in 2020, and 2021, we grew past $4 billion. And, and our healthcare and packaging business, as we reflected today, the beginning of the year, we thought we would do about $5 billion. And those numbers are holding. And by the way, that's with the handicap on the supply chain dynamics, and what the team's doing there has gone so far beyond base electronics, when you think about all the things we're doing in the pharma space, when you think about what we're doing in terms of precision machining, and then also next evolution, 3D printing in terms of orthopaedics, it's, it's really, really fascinating to me. So it's an area of our business that gets a lot of attention, both internally and externally. And it's very, very material to the next couple of years for the company.